Literature DB >> 24191430

Diagnosing and managing inflammatory bowel disease.

Arash Assadsangabi1, Alan J Lobo.   

Abstract

The two major types of inflammatory bowel disease (IBD) are ulcerative colitis and Crohn's disease. Both are characterised by a relapsing and remitting course. In ulcerative colitis the mucosal inflammation affects the rectum and to a variable extent the areas proximal to the rectum in a continuous pattern. Crohn's disease is characterised by discontinuous areas of transmural inflammation that can affect any part of the GI tract but most frequently involves the distal small intestine and proximal colon. IBD has a prevalence of around 400 per 100,000 in the UK. There is a bimodal age of presentation with an initial peak in the second and third decades of life followed by another peak in the sixth decade. Acute ulcerative colitis typically presents with bloody diarrhoea with the passage of mucus, urgency and cramping abdominal pain. A severe attack is usually considered to be associated with bloody stools six times a day or more plus one of the features of systemic toxicity. Severe attacks require intensive inpatient treatment. Inflammatory markers in the blood are not always raised in ulcerative colitis. The diagnosis is confirmed by typical histological features on biopsy. Crohn's disease presents with a typical combination of abdominal pain, diarrhoea and weight loss. Pain or fever may also signify the development of an abscess and stricture formation will lead to obstructive symptoms. Perianal disease in the form of abscesses or fistulae may affect 35-45% of patients during the course of their disease. Because of the chronic and, at times, debilitating nature of IBD special attention to the psychosocial aspects of the disease is very important.

Entities:  

Mesh:

Year:  2013        PMID: 24191430

Source DB:  PubMed          Journal:  Practitioner        ISSN: 0032-6518


  8 in total

Review 1.  Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.

Authors:  Yu Jin; Yan Lin; Lian-Jie Lin; Chang-Qing Zheng
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

2.  Intestinal Ultrasonography as a Tool for Monitoring Disease Activity in Patients with Ulcerative Colitis.

Authors:  Milica Stojkovic Lalosevic; Aleksandra Sokic Milutinovic; Vera Matovic Zaric; Iva Lolic; Aleksandar Toplicanin; Sanja Dragasevic; Mirjana Stojkovic; Marija Stojanovic; Marko Aleksic; Mihailo Stjepanovic; Jelena Martinov Nestorov; Dusan Dj Popovic; Tijana Glisic
Journal:  Int J Clin Pract       Date:  2022-07-09       Impact factor: 3.149

Review 3.  Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management.

Authors:  Pegah Hosseini-Carroll; Monica Mutyala; Abhishek Seth; Shaheen Nageeb; Demiana Soliman; Moheb Boktor; Ankur Sheth; Jonathon Chapman; James Morris; Paul Jordan; Kenneth Manas; Felix Becker; Jonathan Steven Alexander
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

4.  Efficacy of herbal medicine (Gegen Qinlian Decoction) on ulcerative colitis: A systematic review of randomized controlled trials.

Authors:  Yuling Fan; Wen Yi; Han Huang; Zhigang Mei; Zhitao Feng
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

5.  Protection against ulcerative colitis and colorectal cancer by evodiamine via anti‑inflammatory effects.

Authors:  Yongfeng Zhang; Yaqin Zhang; Yang Zhao; Wanyue Wu; Weiqi Meng; Yulin Zhou; Ye Qiu; Chenliang Li
Journal:  Mol Med Rep       Date:  2022-04-01       Impact factor: 2.952

6.  An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis.

Authors:  N Selcan Turker; Pedram Heidari; Raju Kucherlapati; Melanie Kucherlapati; Umar Mahmood
Journal:  Theranostics       Date:  2014-07-01       Impact factor: 11.556

Review 7.  Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis.

Authors:  Paweł Moćko; Paweł Kawalec; Beata Smela-Lipińska; Andrzej Pilc
Journal:  Arch Med Sci       Date:  2016-08-24       Impact factor: 3.318

Review 8.  An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis.

Authors:  Paweł Kawalec; Andrzej Pilc
Journal:  Arch Med Sci       Date:  2016-03-22       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.